How Risdiplam Defies SMA “Natural History” in Type 1 Infants, According to FIREFISH Study Data

Forums moderator DeAnn Runge shares her experience of getting Spinraza amidst the COVID pandemic. SMA News Today’s multimedia associate, Price Wooldridge, discusses how Risdiplam defies SMA “natural history” in type 1 infants, according to FIREFISH study data. Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/